Does celecoxib with sodium valproate have an augmentation effect on acute mania in bipolar disorder? A double-blind controlled clinical trial in Iran.

["Inflammatory processes in the brain play a role in acute mania etiopathogenesis. There is little evidence indicating the efficacy of celecoxib adjuvant therapy in treatmenting of manic episodes of bipolar disorder. Therefore, this clinical trial aimed to assess the celecoxib effect on treating acute mania. In a double-blind, placebo-controlled trial, 58 patients meeting the criteria for acute mania were enrolled. After considering eligibility, 45 patients were included in the study and randomly divided into two groups. The first group (23 patients) received sodium valproate 400\u2009mg\/day along with celecoxib 400\u2009mg\/day, and the second group (22 patients) received sodium valproate 400\u2009mg\/day and a placebo. The subjects were evaluated by the Young Mania Rating Scale (YMRS) at the beginning of the study and 9, 18, and 28\u2009days following the initiation of the medication. Evaluation of baseline factors indicated a significant difference in age ( P \u2009=\u20090.01) and psychiatric history ( P \u2009=\u20090.02) between the two groups. However, other factors were similar between groups ( P \u2009\u2265\u20090.05). Comparing the YMRS score between celecoxib and placebo groups revealed no significant difference on days 0, 9, 18, and 28. However, the YMRS score at the end of the study decreased by 16.05\u2009\u00b1\u20097.65 in the intervention group ( P \u2009<\u20090.001) and 12.50\u2009\u00b1\u20095.98 in controls ( P \u2009<\u20090.001) compared to the baseline, the trend of change was not significant between the two groups during the time of the study ( F \u2009=\u20090.38; P \u2009=\u20090.84). Although celecoxib adjuvant therapy indicated no considerable side effects, a longer treatment duration may be needed to detect its beneficial effects for treating acute mania in bipolar patients. Trial registration: Iran clinical trial register: IRCT20200306046708N1.",{"copyright":"Copyright \u00a9 2023 Wolters Kluwer Health, Inc. All rights reserved."}]